Myo Inositol Experiences

MB50

Member
Joined
Mar 2, 2016
Messages
62
Location
Washington, DC
Just wondering if anybody here has any experience with myo inositol supplementation? It seems to be extremely helpful for PCOS symptoms and current issues some forum females have dealt with-- high androgens and high estrogen (which is what my gf is currently battling after stopping the BCP). Studies I was reading through seem to show much better insulin sensitivity and reduced FSH, LH, testosterone, and androstenedione. Interestingly, some people do seem to take it for mood and OCD at higher doses (16-20g) and anecdotal reports are very impressive.

I know myo inositol can be made endogenously as needed, but I wonder if environmental factors (sometimes BCP) can screw up the normal regulation of it. Another thing I was wondering and would be curious for somebody more intelligent to comment on: I am wondering if the reduction in testosterone in females would also happen in males? I couldn't find any studies that measured males' hormones following supplementation, but I wonder if the reduced testosterone in females is due to better hormonal regulation and insulin control or if the same reduction in T is likely to happen to males. Again, this is going to require some speculation since there isn't much evidence.
 

InChristAlone

Member
Joined
Sep 13, 2012
Messages
5,955
Location
USA
I found this website on anxiety treatments that talks about myo-inositol:
MYO-INOSITOL’s primary mechanism of action specifically with regards to its ANXIOLYTIC effects appears to be that of UPREGULATION of the SEROTONIN RECEPTORS; possibly through functioning as a PRECURSOR to the PHOSPHATIDYLINOSITOL CYCLE, which is the second messenger system for several neurotransmitters including several subtypes of SEROTONIN RECEPTORS.

MYO-INOSITOL does not appear to affect actual MONOAMINE levels, which would include SEROTONIN and GABA.

The scientific evidence supporting MYO-INOSITOL’s ANXIOLYTIC efficacy is somewhat inconclusive, in that there exists some conflicting evidence supporting its ANXIOLYTIC effects; this is further compounded by mixed anecdotal user feedback reports, in that some individuals report that they find it to be an effective ANXIOLYTIC, whereas others report no ANXIOLYTIC effect whatsoever. There are even

Furthermore, there is substantiated evidence that MYO-INOSITOL’s ANXIOLYTIC efficacy is somewhat dependent on firstly what is the SCALE of the ANXIETY, in that MYO-INOSITOL appears to be significantly less effective in treating ACUTE ANXIETY than it is in treating CHRONIC ANXIETY; and secondly on what is the TYPE of the ANXIETY DISORDER, in that for example it appears that MYO-INOSITOL may be somewhat effective in treating OBSESSIVE-COMPULSIVE DISORDER (OCD) and PANIC DISORDER, but less effective in treating STRESS RELATED ANXIETY, such as POST TRAUMATIC STRESS DISORDER (PTSD).

SAFETY & SIDE EFFECTS:

MYO-INOSITOL is SAFE and NON-TOXIC; no changes have been found in studies of hematology, kidney, or liver function.

However, it should be noted that SIDE EFFECTS include: INCREASED ANXIETY, INSOMNIA, and GASTROINTESTINAL UPSET, including (but not limited to) DIARRHEA, NAUSEA, FLATULENCE, and STOMACH UPSET.

Some of these SIDE EFFECTS can occur upon commencement of usage, but then subsequently dissipate within two weeks consistent usage. For example, INOSITOL may for some (but not all) people initially induce ANXIOGENIC effects; however, in such instances the ANXIOGENIC effects typically vanish entirely within two weeks usage, and are subsequently replaced with ANXIOLYTIC effects. It is therefore recommended if trying out INOSITOL for treating ANXIETY to take it consistently for a period of at least 3-4 weeks in order to properly evaluate its therapeutic effects.

CONTRAINDICATIONS:

MYO-INOSITOL has been demonstrated to EXACERABATE pre-existing symptoms of ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY (ADDH), and hence should not be used by ADDH sufferers.

MYO-INOSITOL should be avoided by pregnant women, since high dose MYO-INOSITOL may induce uterine contractions.

Therefore, taking into consideration all of the above information, I have added INOSITOL to the ‘POSSIBLY SAFE & EFFECTIVE TO TAKE’ LIST for treating ANXIETY.

See the following:

Behav Brain Res. 2001 Jan 8;118(1):77-83.

The antidepressant activity of inositol [Myo-Inositol] in the forced swim test involves 5-HT(2) receptors.

Einat H, Clenet F, Shaldubina A, Belmaker RH, Bourin M.

Source
Beer Sheva Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, P.O. Box 4600, Beer Sheva, Israel.

Abstract
The effect of Inositol [Myo-Inositol] as an antidepressant was previously demonstrated in both animal models of depression-like behavior and in clinical trials. Unlike most antidepressant drugs, Inositol [Myo-Inositol] does not have a clear target in the synapse and was not demonstrated to alter monoamine levels in the brain. The present study attempted to draw a psychopharmacological profile of Inositol [Myo-Inositol]'s behavioral effects by exploring the interactions between the drug and specific receptor agonists and antagonists in the forced swim test. Rats received Inositol [Myo-Inositol] treatment (or control) in combination with the serotonergic metabolism inhibitor PCPA or with the noradrenergic neurotoxin DSP-4. Results indicated that PCPA but not DSP-4 abolished the ability of Inositol [Myo-Inositol] to cause a reduction in immobility time in the forced swim test. In mice, the specific 5-HT(2A)/5-HT(2C) antagonist ritanserin, but not the 5-HT(1A)/5-HT(1B)/beta adrenergic antagonist pindolol, abolished Inositol [Myo-Inositol]'s effect in the forced swim test. The 5-HT(2A)/5-HT(2C) agonist DOI and the 5-HT(1A) agonist 8-OH-DPAT did not have any significant effects on Inositol [Myo-Inositol]'s activity. The present data indicates that the antidepressant effect of Inositol [Myo-Inositol] may involve 5-HT(2) receptors. It is thus possible that the effects of reuptake antidepressant drugs and the effects of Inositol [Myo-Inositol] may have a common final pathway.

PMID: 11163636
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Brain Res. 1993 Dec 24;631(2):349-51.

Myo-inositol reduces serotonin (5-HT2) receptor induced homologous and heterologous desensitization.

Rahman S, Neuman RS.

Source
Faculty of Medicine, Memorial University, St. John's, Nfld, Canada.

Abstract
The effect of myo-inositol was examined on 5-HT2 receptor mediated facilitation of NMDA depolarization of rat neocortical neurons in vitro. Myo-inositol (1-10 mM) potentiated the 5-HT facilitation, the potentiation increasing linearly with log 5-HT concentration. Myo-inositol also eliminated 5-HT induced heterologous desensitization of muscarinic and alpha 1-adrenergic receptor mediated facilitation. Our findings suggest that 5-HT induced homologous and heterologous desensitization results in part from depleting phosphoinositide substrate.

PMID: 8131066
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Metab Brain Dis. 2004 Jun;19(1-2):51-70.

Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells.

Brink CB, Viljoen SL, de Kock SE, Stein DJ, Harvey BH.

Source
Division of Pharmacology, Potchefstroom Campus of the North-West University, Potchefstroom, South Africa.

Abstract
myo-Inositol (mI) is a key metabolic precursor to the phospoinositide (PI) metabolic pathway as a key component of central G-protein coupled receptor signaling systems, including several subtypes of adrenergic, cholinergic, serotonergic and metabotropic glutamatergic receptors. High dose mI [Myo-Inositol] has also been shown to be clinically effective in the treatment of obsessive-compulsive disorder, as well as panic and depression, although its mechanism of action remains elusive. The current study aimed to investigate the possible modulatory role of mI [Myo-Inositol] versus fluoxetine or imipramine pretreatments on serotonin-2A receptor (5HT2A-R) and muscarinic acetylcholine receptor (mAChR) function and binding in in vitro systems. After pretreating human neuroblastoma cells with different concentrations of mI [Myo-Inositol], fluoxetine, or imipramine, receptor function was measured by second messenger [3H]-IPx accumulation and [35S]-GTPgammaS binding to G alpha(q) protein. Total [3H]-mI [Myo-Inositol] uptake into cells was measured, as well as specific receptor binding to determine receptor binding after the pretreatments. Results suggest that mI [Myo-Inositol] reduces 5HT2A-R function at the receptor-G protein level. While fluoxetine also reduced 5HT2A-R function, but to a lesser degree, imipramine increased 5HT2A-R function, which may explain why mI [Myo-Inositol] seems to be effective exclusively in selective serotonin reuptake inhibitor-sensitive disorders. In addition mI [Myo-Inositol], and at high concentrations fluoxetine and imipramine, also reduces mAChR function. Furthermore the results suggest that the attenuating effect of mI [Myo-Inositol] on mAChRs is partially dependent on the PI metabolic pathway. The data provide novel information on understanding the mechanism of action of mI [Myo-Inositol] in depression and related anxiety disorders and added to the evidence suggesting a role for the cholinergic system in the pathophysiology of depression.

PMID: 15214506

-----------------------------------------------------------------------------------------------------------------------------------------------------------


Eur Neuropsychopharmacol. 1997 May;7(2):147-55.

Controlled trials of inositol [Myo-Inositol] in psychiatry.

Levine J.

Source
Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheva, Israel.

Abstract
Inositol [Myo-Inositol] is a simple polyol precursor in a second messenger system important in the brain. Cerebrospinal fluid Inositol [Myo-Inositol] has been reported as decreased in depression. A double-blind controlled trial of 12 g daily of Inositol [Myo-Inositol] in 28 depressed patients for four weeks was performed. Significant overall benefit for Inositol [Myo-Inositol] compared to placebo was found at week 4 on the Hamilton Depression Scale. No changes were noted in hematology, kidney or liver function. Since many antidepressants are effective in panic disorder, twenty-one patients with panic disorder with or without agoraphobia completed a double-blind, placebo-controlled, four week, random-assignment crossover treatment trial of Inositol [Myo-Inositol] 12 g per day. Frequency and severity of panic attacks and severity of agoraphobia declined significantly with Inositol [Myo-Inositol] compared to placebo. Side-effects were minimal. Since serotonin re-uptake inhibitors benefit obsessive compulsive disorder (OCD) and Inositol [Myo-Inositol] is reported to reverse desensitization of serotonin receptors, thirteen patients with OCD completed a double-blind controlled crossover trial of 18 g Inositol [Myo-Inositol] or placebo for six weeks each. Inositol [Myo-Inositol] significantly reduced scores of OCD symptoms compared with placebo. A controlled double-blind crossover trial of 12 g daily of Inositol [Myo-Inositol] for a month in twelve anergic schizophrenic patients, did not show any beneficial effects. A double-blind controlled crossover trial of 6 g of Inositol [Myo-Inositol] daily vs. glucose for one month each was carried out in eleven Alzheimer patients, with on clearly significant therapeutic effects. Antidepressant drugs have been reported to improve attention deficit disorder (ADDH) with hyperactivity symptomatology. We studied oral Inositol [Myo-Inositol] in children with ADDH [Attention Deficit Disorder with Hyperactivity] in a double-blind, crossover, placebo-controlled manner. Eleven children, mean age 8.9 +/- 3.6 years were enrolled in an eight week trial of Inositol [Myo-Inositol] or placebo at a dose of 200 mg/kg body weight. Results show a trend for aggravation of the syndrome with myo-inositol as compared to placebo. Recent studies suggest that serotonin re-uptake inhibitors are helpful in at least some symptoms of autism. However a controlled double-blind crossover trial of Inositol [Myo-Inositol] 200 mg/kg per day showed no benefit in nine children with autism. Cholinergic agonists have been reported to ameliorate electroconvulsive therapy (ECT)-induced memory impairment. Inositol [Myo-Inositol] metabolism is involved in the second messenger system for several muscarinic cholinergic receptors. Inositol [Myo-Inositol] 6 g daily was given in a crossover-double-blind manner for five days before the fifth or sixth ECT to a series of twelve patients, without effect. These results suggest that Inositol [Myo-Inositol] has therapeutic effects in the spectrum of illness responsive to serotonin selective re-uptake inhibitors, including depression, panic and OCD, and is not beneficial in schizophrenia, Alzheimer's, ADDH [Attention Deficit Disorder with Hyperactivity], autism or ECT-induced cognitive impairment.

PMID: 9169302
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Am J Psychiatry. 1996 Sep;153(9):1219-21.

Inositol [Myo-Inositol] treatment of obsessive-compulsive disorder.

Fux M, Levine J, Aviv A, Belmaker RH.

Source
Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheva, Israel.

Abstract

OBJECTIVE:
Earlier studies reported that inositol [Myo-Inositol], a simple polyol second messenger precursor, was effective in controlled trials for patients with depression and panic. In this study its effectiveness in obsessive-compulsive disorder was investigated.

METHOD:
Thirteen patients with obsessive-compulsive disorder completed a double-blind, controlled crossover trial of 18 g/day of inositol [Myo-Inositol] or placebo for 6 weeks each.

RESULTS:
The subjects had significantly lower scores on the Yale-Brown Obsessive Compulsive Scale when taking inositol [Myo-Inositol] than when taking placebo.

CONCLUSIONS:
The authors conclude that inositol [Myo-Inositol] is effective in depression, panic, and obsessive-compulsive disorder, a spectrum of disorders responsive to selective serotonin reuptake inhibitors.

PMID: 8780431
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Am J Psychiatry. 1995 Jul;152(7):1084-6.

Double-blind, placebo-controlled, crossover trial of Inositol [Myo-Inositol] treatment for panic disorder.

Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH.
Source

Soroka Medical Center, Kupat Holim Sick Fund of the Histadrut, Beersheba, Israel.
Abstract

OBJECTIVE:

Because they found in an earlier study that Inositol [Myo-Inositol], an important intracellular second-messenger precursor, was effective against depression in open and double-blind trials, the authors studied its effectiveness against panic disorder.
METHOD:

Twenty-one patients with panic disorder with or without agoraphobia completed a double-blind, placebo-controlled, 4-week, random-assignment crossover treatment trial of 12 g/day of Inositol [Myo-Inositol].
RESULTS:

The frequency and severity of panic attacks and the severity of agoraphobia declined significantly more after Inositol [Myo-Inositol] than after placebo administration. Side effects were minimal.
CONCLUSIONS:

The authors conclude that Inositol [Myo-Inositol]'s efficacy, the absence of significant side effects, and the fact that Inositol [Myo-Inositol] is a natural component of the human diet make it a potentially attractive therapeutic for panic disorder.
PMID: 7793450
-----------------------------------------------------------------------------------------------------------------------------------------------------------

J Clin Psychopharmacol. 2001 Jun;21(3):335-9.

Double-blind, controlled, crossover trial of inositol [Myo-Inositol] versus fluvoxamine for the treatment of panic disorder.

Palatnik A, Frolov K, Fux M, Benjamin J.

Source
Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheba, Israel.

Abstract
Only 70% of patients respond to current treatments for panic disorder, and many discontinue drugs because of side effects. myo-Inositol, a natural isomer of glucose and a precursor for the second-messenger phosphatidyl-inositol system, has previously been found superior to placebo in the treatment of depression, panic disorder, and obsessive-compulsive disorder (OCD), but a direct comparison with an established drug has never been performed. A double-blind, controlled, random-order crossover study was undertaken to compare the effect of inositol [Myo-Inositol] with that of fluvoxamine in panic disorder. Twenty patients completed 1 month of inositol [Myo-Inositol] up to 18 g/day and 1 month of fluvoxamine up to 150 mg/day. Improvements on Hamilton Rating Scale for Anxiety scores, agoraphobia scores, and Clinical Global Impressions Scale scores were similar for both treatments. In the first month, inositol [Myo-Inositol] reduced the number of panic attacks per week (mean and SD) by 4.0 (2) compared with a reduction of 2.4 (2) with fluvoxamine (p = 0.049). Nausea and tiredness were more common with fluvoxamine (p = 0.02 and p = 0.01, respectively). Because inositol [Myo-Inositol] is a natural compound with few known side effects, it is attractive to patients who are ambivalent about taking psychiatric medication. Continuing reports of inositol's [Myo-Inositol’s] efficacy in the treatment of depression, panic disorder, and OCD should stimulate replication studies.

PMID: 11386498
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Anxiety. 1996;2(1):51-2.

Inositol [Myo-Inositol] treatment of post-traumatic stress disorder.

Kaplan Z, Amir M, Swartz M, Levine J.

Source
Beer-Sheva Mental Health Center, Ben-Gurion University of the Negev, Israel.

Extract from Full Text

INTRODUCTION
Inositol [Myo-Inositol] is a second messenger system precursor that can affect the function of several neurotransmitters including serotonin (Rahman and Newman, 1993). Inositol [Myo-Inositol] has been shown in controlled double-blind studies to ameliorate symptoms of depression (Levine et al., 1995) and panic disorder (Benjamin et al., 1995). Several antidepressants and antipanic medications were reported to have some effect on post-traumatic stress disorder (PTSD; Katz et al., 1995). We therefore carried out a study of Inositol [Myo-Inositol] in PTSD.

RESULTS
Table 1 shows the means and standard deviations for the overall score and the two subscales of the IES for Inositol [Myo-Inositol] and placebo. No significant difference was found between Inositol [Myo-Inositol] and placebo for the improvement score (difference between baseline and four weeks) mean and S.D. for the overall IES score (3.76 *6.42 for Inositol [Myo-Inositol] and -.38 f 8.46 for placebo), for the avoidance subscale (.15 c 3.81 for Inositol [Myo-Inositol] and -.77 –c 5.95 for placebo) or for the intrusion subscale (3.62 * 3.75 for Inositol [Myo-Inositol] and .38 c 5.72 for placebo).

Among the eight patients at the Abarbanel clinic we did not find any significant differences between the improvement score for Inositol [Myo-Inositol] and placebo on the Hamilton Depression Scale (mean and S.D. = 2.5 f 1.9 for Inositol [Myo-Inositol] and 3.1 -c 3.1 for placebo, p > 0.05) or for the Hamilton Anxiety Scale (mean and S.D. = 5.3 * 3.5 for Inositol [Myo-Inositol] and 4.4 f 5.0 for placebo, p 1 0.05).

For the five patients at the Beer-Sheva clinic we found a significant difference on the depression subscale of the SCL-90 (mean and S.D. = 3.4 6.03 for Inositol [Myo-Inositol] and -5.6 2 2.70 for placebo, p = 0.04, one-tailed), but no difference on the anxiety subscale (mean and S.D. =.80 2 2.28 for Inositol [Myo-Inositol] and .40 8.62 for placebo, p > 0.05). All the analyses were done by paired t-tests.

DISCUSSION
This preliminary double-blind crossover study showed no effect of Inositol [Myo-Inositol] on PTSD core symptoms of intrusion and avoidance. However, depression was lowered in the Beer-Sheva subsample of five patients as a resultof the Inositol [Myo-Inositol] treatment. The results from the present study are in line with several other studies that did not find any effect of pharmacological treatment on intrusion and avoidance in PTSD (Katz et al., 1995)…

PMID: 9160600
-----------------------------------------------------------------------------------------------------------------------------------------------------------

World J Biol Psychiatry. 2002 Jul;3(3):147-9.

Myo-inositol has no beneficial effect on premenstrual dysphoric disorder.

Nemets B, Talesnick B, Belmaker RH, Levine J.

Source
Department of Psychiatry, Faculty of Health Sciences, Ben Gurion University of the Negev, Israel.

Abstract
Inositol [Myo-Inositol], a simple isomer of glucose, which serves as a precursor in the phosphatidyl-inositol (PI) second messenger cycle, was shown to be effective in double-blind, placebo-controlled studies of depression, panic and obsessive compulsive disorders as well as in bulimia. The following study was designed to investigate whether inositol [Myo-Inositol] has beneficial effects in another disorder shown to be responsive to SSRIs: premenstrual dysphoric disorder (PMDD). Eleven female patients with PMDD diagnosed according to DSM-IV participated in a cross-over, double-blind, placebo-controlled trial. The active drug was myo-inositol, 12 g daily, whereas placebo was d-glucose administered at the same dose. Each drug was given during the luteal phase only (14 days prior to menses). For each patient treatment alternated between these two drugs for six menstrual cycles. No beneficial effect was demonstrated for inositol [Myo-Inositol] over placebo.

PMID: 12478879

The ABOVE study indicates that MYO-INOSITOL is INEFFECTIVE in treating PREMENSTRUAL DYSPHORIC DISORDER (PMDD); whereas the BELOW study indicates that MYO-INOSITOL is EFFECTIVE in treating PREMENSTRUAL DYSPHORIC DISORDER (PMDD); hence, there currently is conflicting evidence regards MYO-INOSITOL’s efficacy in treating PMDD.

-----------------------------------------------------------------------------------------------------------------------------------------------------------

Hum Psychopharmacol. 2011 Oct;26(7):526-30. doi: 10.1002/hup.1241.

Myo-inositol in the treatment of premenstrual dysphoric disorder.

Gianfranco C, Vittorio U, Silvia B, Francesco D.

Source
AGUNCO Obstetrics and Gynecology Centre, via G. Cassiani, Rome, Italy. [email protected]

Abstract

OBJECTIVE:
Premenstrual dysphoric disorder (PMDD) is a mood disorder disrupting social and/or occupational life of affected women. Premenstrual dysphoric disorder etiology is unknown, although a pivotal role is played by the serotoninergic system. Indeed, one of the most effective treatments is selective serotonin reuptake inhibitors. Several studies have proposed a selective serotonin reuptake inhibitor-like role for myo-inositol, likely due to the fact that myo-inositol is the second messenger of serotonin. In the present study, we aimed to investigate the effect of myo-inositol in the treatment of PMDD.

METHODS:
We used a two-phase clinical trial approach (phase I: placebo washout; phase II: comparisons between treatment and placebo) and treated PMMD patients with two different myo-inositol formulations: powder or soft gel capsules. We decided to test these two formulations because according to the manufacturer, 0.6 g of myo-inositol in soft gel capsule has a pharmacokinetic equivalent to 2 g of myo-inositol in powder.

RESULTS:
Our results showed a significant improvement of three different scales: a reduction in the Daily Symptoms Records scale and an improvement of the Hamilton Depression Rating and Clinical Global Impression-Severity of Illness scales. Results were similar for both formulations.

CONCLUSIONS:
In the present study, by using a new pharmaceutical formulation, we were able to clearly prove the efficacy of myo-inositol in PMDD [premenstrual dysphoric disorder].

PMID: 22031267

-----------------------------------------------------------------------------------------------------------------------------------------------------------


J Neural Transm. 2000;107(2):241-53.

The anxiolytic effect of chronic inositol [Myo-Inositol] depends on the baseline level of anxiety.

Kofman O, Einat H, Cohen H, Tenne H, Shoshana C.

Source
Department of Behavioral Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Abstract
Inositol [Myo-Inositol], a precursor for membrane phosphoinositides involved in signal transduction, has been found to be clinically effective in a number of psychiatric disorders and to reverse behavioural effects of lithium. To gain insight into the mechanism of action of inositol [Myo-Inositol], it is critical to establish its efficacy in animal models. Following the initial report by Cohen et al. (1997b) that inositol [Myo-Inositol] was anxiolytic in the elevated plus maze model of anxiety, the effect of chronic intraperitoneal and chronic dietary inositol [Myo-Inositol] administration in rats was tested in four experiments. There was a significant increase in closed arm and total arm entries following chronic injection of inositol [Myo-Inositol], but no effect of inositol [Myo-Inositol] when it was given chronically in rat chow. Because the first 2 experiments suggested that the mode of drug administration affected the control levels of anxiety (open arm entries and time in open arms) in control groups, the effect of chronic dietary inositol [Myo-Inositol] was tested in rats that were exposed to a mild and a more severe form of stress. Chronic saline injections elevated anxiety in the plus maze, which was only marginally affected by chronic dietary inositol [Myo-Inositol]. Following 3 weeks administration of 5% dietary inositol [Myo-Inositol] rats were pre-exposed to a cat. There was a clear increase in number of entries into open arms, suggesting an anxiolytic effect of inositol [Myo-Inositol].

PMID: 10847563
-----------------------------------------------------------------------------------------------------------------------------------------------------------

J Affect Disord. 2001 Jan;62(1-2):113-21.

The effects of inositol [Myo-Inositol] treatment in animal models of psychiatric disorders.

Einat H, Belmaker RH.

Source
Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheva, Israel.

Abstract
Clinical trials indicate that inositol [Myo-Inositol] may be effective in the treatment of patients with depression, panic disorder and obsessive compulsive disorder (OCD), but not in the treatment of patients with schizophrenia, Alzheimer's disease, ADHD or autism. This spectrum of clinical action parallels that of serotonin selective reuptake inhibitors (SSRIs), but inositol [Myo-Inositol] is a precursor in the phosphatidylinositol cycle, a second messenger system distal to the receptor for 5HT-2. To study its mechanism of therapeutic action there is a need to test inositol's [Myo-Inositol’s] activity in animal models of psychopathology. In rats, chronic inositol [Myo-Inositol] was demonstrated to increase activity levels, reduce immobility time in the forced swim test and in the reserpine-induced hypoactivity models of depression, and reduce anxiety-like behaviors in the elevated plus-maze. The reduction in anxiety-like behaviors appears to be related to baseline levels of activity. Inositol [Myo-Inositol] treatment was not observed to have any effect on amphetamine-induced hyperactivity, apomorphine-induced stereotypy, or on the performance of memory tasks by monkeys. Clinical controlled trials of inositol [Myo-Inositol] in patients with depression, panic disorder, and OCD were small, and positive psychoactive effects in animals clearly strengthen the case for further clinical trials and potential for general therapeutic use in humans.

PMID: 11172878
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Am J Psychiatry. 1995 May;152(5):792-4.

Double-blind, controlled trial of inositol [Myo-Inositol] treatment of depression.

Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH.

Source
Yehuda Abarbanel Mental Health Center, Bat Yam, Israel.

Abstract

OBJECTIVE:
CSF levels of inositol [Myo-Inositol] have been reported to be lower than normal in depressed subjects. The authors administered inositol [Myo-Inositol] to depressed patients in a double-blind, controlled trial.

METHOD:
Under double-blind conditions, 12 g/day of inositol [Myo-Inositol] (N = 13) or placebo (N = 15) was administered to depressed patients for 4 weeks.

RESULTS:
The overall improvement in scores on the Hamilton Depression Rating Scale was significantly greater for inositol [Myo-Inositol] than for placebo at week 4. No changes were noted in hematology or in kidney or liver function.

CONCLUSIONS:
This may be the first use of the precursor strategy for a second messenger rather than a neurotransmitter in treating depression. Although inositol [Myo-Inositol] had a significant antidepressant effect in this study, replication is crucial.

PMID: 7726322
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Cochrane Database Syst Rev. 2004;(2):CD004049.

Inositol [Myo-Inositol] for depressive disorders.

Taylor MJ, Wilder H, Bhagwagar Z, Geddes J.

Source
Department of Psychiatry, University of Oxford, Neurosciences Building, Warneford Hospital, Oxford, Oxfordshire, UK, OX3 7JK.

Abstract

BACKGROUND:
There are a number of effective interventions for the treatment of depression. It is possible that the efficacy of these treatments will be improved further by the use of adjunctive therapies such as inositol [Myo-Inositol].

OBJECTIVES:
1. To determine the effectiveness of inositol [Myo-Inositol] in the treatment of depression.2. To determine the adverse effects and acceptability of treatment with inositol [Myo-Inositol].

SEARCH STRATEGY:
The Cochrane Controlled Trials Register (CCTR), The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR) incorporating results of group searches of EMBASE, MEDLINE, LILACS, CINAHL, PSYNDEX and PsycLIT were searched. Reference lists of relevant papers and major textbooks of affective disorder were checked. Experts in the field and pharmaceutical companies were contacted regarding unpublished material.

SELECTION CRITERIA:
All randomised controlled trials that compare treatment with inositol [Myo-Inositol], whether as monotherapy or adjunctive therapy, to an alternative treatment, whether another antidepressant medication or placebo, for patients with a diagnosis of depressive disorder (diagnosed according to explicit criteria).

DATA COLLECTION AND ANALYSIS:
Data were independently extracted from the original reports by two reviewers. Statistical analysis was conducted using Review Manager version 4.2.1.

MAIN RESULTS:
Four trials were identified, with a total of 141 participants. These were short term trials of double-blind design. The trials did not show clear evidence of a therapeutic benefit, nor any evidence of poor acceptability.

REVIEWERS' CONCLUSIONS:
It is currently unclear whether or not inositol [Myo-Inositol] is of benefit in the treatment of depression. Ongoing studies should reduce this uncertainty.

PMID: 15106232
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Behav Brain Res. 2001 Jan 8;118(1):77-83.

The antidepressant activity of inositol [Myo-Inositol] in the forced swim test involves 5-HT(2) receptors.

Einat H, Clenet F, Shaldubina A, Belmaker RH, Bourin M.

Source
Beer Sheva Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, P.O. Box 4600, Beer Sheva, Israel.

Abstract
The effect of inositol [Myo-Inositol] as an antidepressant was previously demonstrated in both animal models of depression-like behavior and in clinical trials. Unlike most antidepressant drugs, inositol [Myo-Inositol] does not have a clear target in the synapse and was not demonstrated to alter monoamine levels in the brain. The present study attempted to draw a psychopharmacological profile of inositol's behavioral effects by exploring the interactions between the drug and specific receptor agonists and antagonists in the forced swim test. Rats received inositol treatment (or control) in combination with the serotonergic metabolism inhibitor PCPA or with the noradrenergic neurotoxin DSP-4. Results indicated that PCPA but not DSP-4 abolished the ability of inositol to cause a reduction in immobility time in the forced swim test. In mice, the specific 5-HT(2A)/5-HT(2C) antagonist ritanserin, but not the 5-HT(1A)/5-HT(1B)/beta adrenergic antagonist pindolol, abolished inositol's effect in the forced swim test. The 5-HT(2A)/5-HT(2C) agonist DOI and the 5-HT(1A) agonist 8-OH-DPAT did not have any significant effects on inositol's [Myo-Inositol’s] activity. The present data indicates that the antidepressant effect of inositol [Myo-Inositol] may involve 5-HT(2) receptors. It is thus possible that the effects of reuptake antidepressant drugs and the effects of inositol [Myo-Inositol] may have a common final pathway.

PMID: 11163636
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Int Clin Psychopharmacol. 1999 Nov;14(6):353-6.

Inositol [Myo-Inositol] augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial.

Seedat S, Stein DJ.
Source

Department of Psychiatry, University of Stellenbosch, Tygerberg, South Africa.
Erratum in
  • Int Clin Psychopharmacol 2000 Jul;1
  • 5(4):244.
Abstract

Inositol [Myo-Inositol], an isomer of glucose and precursor in the phosphatidylinositol cycle, may be effective in a number of psychiatric disorders, including obsessive-compulsive disorder (OCD). There is little data, however, on inositol [Myo-Inositol] as an augmenting agent of serotonin reuptake inhibitors (SRIs) in treatment-refractory patients. Ten OCD patients who had failed to respond to current and previous trials of serotonin reuptake inhibitors participated in open-label trial of inositol [Myo-Inositol] (18 gm/day) [corrected] augmentation for 6 weeks. Symptoms were rated at 2-weekly intervals using the Yale-Brown Obsessive-Compulsive Scale, the Montgomery-Asberg Depression Rating Scale, and the Clinical Global Impressions (CGI) Scale. The majority of patients (n = 7) did not respond to treatment with inositol [Myo-Inositol] augmentation on the CGI improvement item. However, a small number of patients (n = 3) did report a clinically significant response on the CGI improvement item. OCD patients who fail to respond to a number of trials of SRIs may be a particularly treatment-refractory group of subjects. Unfortunately, inositol [Myo-Inositol] augmentation of a SRI did not lead to significant improvement in the majority of such cases. Nevertheless, further research on the mechanism of inositol [Myo-Inositol] efficacy in some patients with anxiety and mood disorders is warranted.

PMID: 10565802
TREATING ANXIETY SAFELY & EFFECTIVELY - Mental Health
 
OP
MB50

MB50

Member
Joined
Mar 2, 2016
Messages
62
Location
Washington, DC
Potential role and therapeutic interests of myo-inositol in metabolic diseases


Abstract
Several inositol isomers and in particular myo-inositol (MI) and D-chiro-inositol (DCI), were shown to possess insulin-mimetic properties and to be efficient in lowering post-prandial blood glucose. In addition, abnormalities in inositol metabolism are associated with insulin resistance and with long term microvascular complications of diabetes, supporting a role of inositol or its derivatives in glucose metabolism. The aim of this review is to focus on the potential benefits of a dietary supplement of myo-inositol, by far the most common inositol isomer in foodstuffs, in human disorders associated with insulin resistance (polycystic ovary syndrome, gestational diabetes mellitus or metabolic syndrome) or in prevention or treatment of some diabetic complications (neuropathy, nephropathy, cataract).

“…Confirming the important role of hyperinsulinemic insulin resistance in the pathogenesis of PCOS, insulin reduction, whether achieved by inhibition of pancreatic insulin release (diazoxide or octreotide) or improvement in peripheral insulin sensitivity (metformin, troglitazone, DCI), is associated with a reduction in circulating androgens, an improvement in ovulatory function, and enhanced fertility in women with PCOS… myo-Inositol, through its insulin-sensitizing effect, was also found to be effective in improving metabolic and hormonal parameters in PCOS women. Previous studies have demonstrated that MI supplementation can restore spontaneous ovarian activity (spontaneous ovulation, menstrual cyclicity restored), and consequently fertility in most women patients with PCOS [13], [61], [62], [63], [64] and [65]. A significant improvement of typical hormonal parameters was observed in PCOS women after MI treatment: decreased LH, FSH, and testosterone circulating levels, and increased SHBG, estrogens and progesterone circulating levels [62], [63], [64] and [66].”

“..Unfer et al. [13] reviewed and analyzed the six Randomized Controlled Trials (RCTs) focused on MI supplementation to improve PCOS hormonal and metabolic disturbances and they provided level Ia evidence of myo-inositol effectiveness (with a dosage of 2–4 g/day for 12–16 weeks in those studies and no side effects reported in these conditions). myo-Inositol mechanism of action appears to be mainly based on improving insulin sensitivity of target tissues, resulting in the reduction of insulinemia which has a positive effect on the reproductive axis (ovulation restoration and oocyte quality improvement) and hormonal functions (reduction of clinical and biochemical hyperandrogenism and of dislipidemia). Of note, myo-inositol positive effect on the reproductive axis could also be related to the pivotal role of I(1,4,5)P3 in the regulation of Ca2+ release during oocytes development which conditions the acquisition of meiotic competence and drives oocytes to the final stages of maturation [4.””

. Concluding remarks
myo-Inositol is a polyol naturally present in eukaryotic cells and is a component of numerous biological molecules, including second messengers like IP3, PIP2/PIP3 and IPGs which makes it essential for numerous biological processes. Abnormalities in its metabolism are associated to pathological states and in particular, MI intracellular deficiency in sciatic nerve, kidney, lens and retina of diabetic subjects probably contribute to the development or aggravation of some diabetes complications in those tissues. Correction of MI intracellular depletion by MI supplement prevented or delayed the development of some microvascular complications of diabetes in the motor nerves and lens in animal models but was inefficient for diabetic nephropathy. Insulin resistance is also associated to excessive urinary excretion of MI and decreased urinary level of DCI. A correlation has even been observed between the decrease in urinary DCI and the severity of insulin resistance. Insulin resistant tissues like skeletal muscles also presented altered DCI to MI ratios and decreased IPGs content, activity and production in response to insulin. Since IPGs are putative mediators of insulin action, their deficit in insulin target tissues probably participate to the development or progression of insulin resistance. Dietary supplement of inositol isomers DCI, d-pinitol or MI were found to be efficient in lowering post-prandial plasma glucose in several animal models of diabetes or insulin resistance. The insulin-mimetic properties of dietary inositol supplements is mainly believed to be related to the production of inositol glycan secondary messengers containing either MI or DCI.



Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial.
BACKGROUND:
Polycystic ovary syndrome is the most common cause of chronic anovulation infertility in women in fertile period, and it's characterized by an increased production of androgens and estrogens. The administration of myo-inositol, a B complex vitamin, was associated with a decreased of serum testosterone and simultaneously, due to its ability to increase insulin sensitivity, women who received myo-inositol showed a great improvement of the ovulary function. Besides, the supplementation of inositol improves the oocytes' quality and increase the number of oocytes collected after ovarian stimulation in patients undergoing IVF (in vitro fertilization).

AIM:
The aim of this study is to determine the effects of myo-inositol on oocyte's quality on a sample of women with polycystic ovary syndrome.

MATERIAL AND METHODS:
The patients were divided into two groups: patients of Group A in-took 2 g of myo-inositol + 200 microg of folic acid (Inofolic, LO.LI. Pharma, Rome, Italy) while Group B only 200 microg of folic acid, both groups took the treatment twice a day, continuously for 3 months.

RESULTS:
At the end of treatment, the number of follicles of diameter > 15 mm, visible at ultrasound during stimulation, and the number of oocytes recovered at the time of pick-ups were found to be significantly greater in the group treated with myo-inositol, so as the aver-age number of embryos transferred and embryo Score S1. Significantly reduced was the average number of immature oocytes (vesicles germ and degenerated oocytes) too.

CONCLUSIONS:
These data suggest that myoinositol may be useful in the treatment of PCOS patients undergoing ovulation induction, both for its insulin-sensitizing activity, and its role in oocyte maturation.




Relationship Between Myo-Inositol Supplementary and Gestational Diabetes Mellitus: A Meta-Analysis.
Abstract

To determine whether myo-inositol supplement will increase the action of endogenous insulin, which is mainly measured by markers of insulin resistance such as homeostasis model assessment of insulin resistance.PubMed, Cochrane Library, Embase, and web of science were comprehensively searched using "gestational diabetes mellitus" and "myo-inositol" to identify relevant studies. Both subject headings and free texts were adopted. The methodological quality of the included studies were assessed and pooled analyzed by the methods recommended by the Cochrane collaboration.A total of 5 trials containing 513 participants were included. There was a significant reduction in aspects of gestational diabetes incidence (risk ratio [RR], 0.29; 95% confidence interval (95% CI), 0.19-0.44), birth weight (mean difference [MD], -116.98; 95% CI, -208.87 to -25.09), fasting glucose oral glucose tolerance test (OGTT) (MD, -0.36; 95% CI, -0.51 to -0.21), 1-h glucose OGTT (MD, -0.63; 95% CI, -1.01 to -0.26), 2-h glucose OGTT (MD, -0.45; 95% CI, -0.75 to -0.16), and related complications (odds ratio [OR], 0.28; 95% CI 0.14-0.58).On the basis of current evidence, myo-inositol supplementation reduces the development of gestational diabetes mellitus (GDM), although this conclusion requires further evaluation in large-scale, multicenter, blinded randomized controlled trials.
 

Nova

Member
Joined
Sep 6, 2015
Messages
93
I know myo inositol can be made endogenously as needed, but I wonder if environmental factors (sometimes BCP) can screw up the normal regulation of it. Another thing I was wondering and would be curious for somebody more intelligent to comment on: I am wondering if the reduction in testosterone in females would also happen in males? I couldn't find any studies that measured males' hormones following supplementation, but I wonder if the reduced testosterone in females is due to better hormonal regulation and insulin control or if the same reduction in T is likely to happen to males. Again, this is going to require some speculation since there isn't much evidence.

I've been researching inositol for the last week or so since I came across it on a "restoring fertility" forum. I have severe PCOS and have suffered from insulin issues for some time now. So I'm definitely no expert, just a voice. :)

Myoinositol is responsible for testosterone production. D-chiro-inositol is responsible for telling the cells to absorb and burn sugars. If either one is out of whack in the female ovary, the woman in question will have issues. If Myinositol is dominant, the woman will over produce testosterone and experience some ugly side effects. DCI levels play a role in insulin resistance and a shortage of DCI often leads to Myoinositol dominance.

Personally, I am pretty sure that my PCOS issues have something to do with Myo/DCI imbalance. I can't say that is the case for every woman who may have it though.

Birth control can really screw up your system. However, I think that what happens is that the ovary becomes inflamed (hormonal imbalances, poor nutrition, chronic stress, etc) and decides that the conditions in the body are not safe for ovulation or pregnancy and shuts itself down. The follicles become irritated because the eggs are just sitting there, basically and that's when the cysts start to form. PCOS cysts can and sometimes do turn cancerous as well, and I think that is because the eggs are meant to be released and they just sit there rotting basically. That can only go on for so long before the body starts to fight back...

The reduction of testosterone that occurs in females when supplementing with Myo seems to be due to Myo converting to DCI and thereby improving the insulin use and sugar utilization within the ovary. I'm not sure that heavy Myo supplementation would produce similar effects ie drop in T levels or whether the drop produced would be significant enough to produce noticeable effects in a man with healthy T levels to begin with.

Bear in mind, I'm no science wizard or anything. I just read a lot and watch too many health vids on the YouTube. ;)
 

Spondive

Member
Joined
Oct 13, 2014
Messages
357
Just my personal anecdote... I have been taking 6k total per day split in two doses and in 2-3 days experienced a huge increase in libido and sexual function in my male parts.. also an increase in happiness and being very outgoing at work.. my last testosterone before taking inositol was 225. I will keep taking and retest in 3 months and post. Overall I have been more impressed than anything I have tried so far
 

Zpol

Member
Joined
Apr 14, 2013
Messages
929
Age
45
Just wondering if anybody here has any experience with myo inositol supplementation? It seems to be extremely helpful for PCOS symptoms and current issues some forum females have dealt with-- high androgens and high estrogen (which is what my gf is currently battling after stopping the BCP). Studies I was reading through seem to show much better insulin sensitivity and reduced FSH, LH, testosterone, and androstenedione. Interestingly, some people do seem to take it for mood and OCD at higher doses (16-20g) and anecdotal reports are very impressive.

I know myo inositol can be made endogenously as needed, but I wonder if environmental factors (sometimes BCP) can screw up the normal regulation of it. Another thing I was wondering and would be curious for somebody more intelligent to comment on: I am wondering if the reduction in testosterone in females would also happen in males? I couldn't find any studies that measured males' hormones following supplementation, but I wonder if the reduced testosterone in females is due to better hormonal regulation and insulin control or if the same reduction in T is likely to happen to males. Again, this is going to require some speculation since there isn't much evidence.

Myoinositol is responsible for testosterone production. D-chiro-inositol is responsible for telling the cells to absorb and burn sugars. If either one is out of whack in the female ovary, the woman in question will have issues. If Myinositol is dominant, the woman will over produce testosterone and experience some ugly side effects. DCI levels play a role in insulin resistance and a shortage of DCI often leads to Myoinositol dominance.
I've read the ratio in 'normal' women is 40:1 Myo to D-chiro and therefore it is thought that this is the ratio women with PCOS should try to achieve if supplementing.

I take Ovasitol. And, yes, it does help PCOS, yay! Bonus is that it also improves my digestion, in fact, the benefit of better digestion is reason I will keep taking it for ever. (TMI... it helps with better b.m.'s)
It's "The only independently tested and certified inositol supplement.
The unique combination of myo- and D-chiro inositol has been shown to be more beneficial than either form of inositol alone."


Plus it's "Dye-free. Gluten-free. 100% inositols. No additives.":
Ovasitol-SFP-Combo_large.jpg
 

ddjd

Member
Joined
Jul 13, 2014
Messages
6,677
I've read the ratio in 'normal' women is 40:1 Myo to D-chiro and therefore it is thought that this is the ratio women with PCOS should try to achieve if supplementing.

I take Ovasitol. And, yes, it does help PCOS, yay! Bonus is that it also improves my digestion, in fact, the benefit of better digestion is reason I will keep taking it for ever. (TMI... it helps with better b.m.'s)
It's "The only independently tested and certified inositol supplement.
The unique combination of myo- and D-chiro inositol has been shown to be more beneficial than either form of inositol alone."


Plus it's "Dye-free. Gluten-free. 100% inositols. No additives.":
Ovasitol-SFP-Combo_large.jpg
is d-chiro inositol only recommended for women? i presume theres no risk for a man to also take it?
 

Zpol

Member
Joined
Apr 14, 2013
Messages
929
Age
45
is d-chiro inositol only recommended for women? i presume theres no risk for a man to also take it?

Men can take it too. It's used for men to treat insulin resistance.
 

mamakitty

Member
Joined
Nov 1, 2021
Messages
516
Location
canada
Men can take it too. It's used for men to treat insulin resistance.
Hi, I have noticed you have mentioned you use ovasitol on multiple threads. I was wondering if you still use it and if it still works for you? Did you get pregnant with it? Did you feel any side effects?
 

Zpol

Member
Joined
Apr 14, 2013
Messages
929
Age
45
Hi, I have noticed you have mentioned you use ovasitol on multiple threads. I was wondering if you still use it and if it still works for you? Did you get pregnant with it? Did you feel any side effects?
Hi. Yes, I still use it. I use it for polycystic ovary syndrome, not trying to conceive (but I've read it's very helpful in that regard). Ovasitol helps regulate my fasting glucose. I stopped taking it for awhile a couple years ago and my FG was measured a little over 100. Got back on it and my FG is in low 90s. Also, it reduces the PCOS pain that I often get around ovulation time.
I do not get any side effects from it.
 

mamakitty

Member
Joined
Nov 1, 2021
Messages
516
Location
canada
Hi. Yes, I still use it. I use it for polycystic ovary syndrome, not trying to conceive (but I've read it's very helpful in that regard). Ovasitol helps regulate my fasting glucose. I stopped taking it for awhile a couple years ago and my FG was measured a little over 100. Got back on it and my FG is in low 90s. Also, it reduces the PCOS pain that I often get around ovulation time.
I do not get any side effects from it.
Thank you so much for replying. I have long suspected I have pcos, so I started taking myo inositol in 2015 or 16. Then I stopped it for a while, but started again end of 2018 and got pregnant early 2019. However, I lost that pregnancy midway due to haematoma which “google” says can happen with assisted pregnancies. So I thought maybe it was the inositol. Anyway I have a healthy baby born in summer of last year. But I’m now feeling my ovulation is off, and my fasting glucose is high. So I am thinking of using ovasitol to regulate my ovulation because I’m going to start ttc seriously soon. I am just a bit scared still of any ill effects in pregnancy.
 

Zpol

Member
Joined
Apr 14, 2013
Messages
929
Age
45
Thank you so much for replying. I have long suspected I have pcos, so I started taking myo inositol in 2015 or 16. Then I stopped it for a while, but started again end of 2018 and got pregnant early 2019. However, I lost that pregnancy midway due to haematoma which “google” says can happen with assisted pregnancies. So I thought maybe it was the inositol. Anyway I have a healthy baby born in summer of last year. But I’m now feeling my ovulation is off, and my fasting glucose is high. So I am thinking of using ovasitol to regulate my ovulation because I’m going to start ttc seriously soon. I am just a bit scared still of any ill effects in pregnancy.

That's great that you had a healthy baby, congratulations! Unfortunately, I don't know too much about the effects of ovasitol during pregnancy. I would assume it would have only positive effects but yeah, if you lost the pregnancy last time you were on it I would probably forgo it during future pregnancies. Or maybe just take it for a few months to see if helps you get your cycle back on track.
High blood sugar is concerning though. There are some other things that could help with that (strength training, higher protein diet... That type of stuff).
 

mamakitty

Member
Joined
Nov 1, 2021
Messages
516
Location
canada
That's great that you had a healthy baby, congratulations! Unfortunately, I don't know too much about the effects of ovasitol during pregnancy. I would assume it would have only positive effects but yeah, if you lost the pregnancy last time you were on it I would probably forgo it during future pregnancies. Or maybe just take it for a few months to see if helps you get your cycle back on track.
High blood sugar is concerning though. There are some other things that could help with that (strength training, higher protein diet... That type of stuff).
Thank you so much, he lights up my whole world!
Yeah, I’m thinking of using ovasitol for a couple cycles. Do you think it’s more efficient to get one month supply or two or three months supply?

Regarding high fasting blood glucose, it’s indeed concerning. But because I got postpartum kidney problem, I had been scared to death of going back to my previous high protein diet. I am also not disciplined enough for strength training. I just want to mediate the glucose issues with diet and walking. I also have very high ldl so I’m really in a big problem here. I’m reading this forum as much as I can to find a solution.
 

Zpol

Member
Joined
Apr 14, 2013
Messages
929
Age
45
I’m reading this forum as much as I can to find a solution.
Oh, I have a suggestion on that that might be helpful ... I found that replacing coconut oil with Extra virgin olive oil on my daily carrot salads improved my ldl cholesterol (plus it tastes better in my opinion). I still use coconut oil for everything else basically.
Do you think it’s more efficient to get one month supply or two or three months supply?
It's definitely more cost effective to get the full three month supply (I'd get the canister not the saches). Plus it could take a full three months to make a noticeable difference.
 

mamakitty

Member
Joined
Nov 1, 2021
Messages
516
Location
canada
Oh, I have a suggestion on that that might be helpful ... I found that replacing coconut oil with Extra virgin olive oil on my daily carrot salads improved my ldl cholesterol (plus it tastes better in my opinion). I still use coconut oil for everything else basically.

It's definitely more cost effective to get the full three month supply (I'd get the canister not the saches). Plus it could take a full three months to make a noticeable difference.

Very good point re it taking three months to make a difference! Thank you. Good thing I didn’t buy the sachets yet haha. I’ll get the canister now.
Regarding olive oil on my carrot salad, I was already doing that because I find coconut oil solidifies too fast and I don’t like the taste. Thanks for the suggestion though!
I’m really reading up on niacin and policosanol for ldl, I’m hoping it works so the doctors don’t force me to take statins. I have even reduced my eggs intake and avoiding bacon and fatty meat for now. Though I have to say I cannot stand lean meat, it tastes like cardboard to me. But I’m so scared of statins, the doctors are really patronising and tyrannical here!
 

Zpol

Member
Joined
Apr 14, 2013
Messages
929
Age
45
Very good point re it taking three months to make a difference! Thank you. Good thing I didn’t buy the sachets yet haha. I’ll get the canister now.
Regarding olive oil on my carrot salad, I was already doing that because I find coconut oil solidifies too fast and I don’t like the taste. Thanks for the suggestion though!
I’m really reading up on niacin and policosanol for ldl, I’m hoping it works so the doctors don’t force me to take statins. I have even reduced my eggs intake and avoiding bacon and fatty meat for now. Though I have to say I cannot stand lean meat, it tastes like cardboard to me. But I’m so scared of statins, the doctors are really patronising and tyrannical here!
Sounds like you have a good plan. I'm researching policosanol as well for my husband who has cardiovascular disease, sounds very promising. He's currently on the statins which makes me so sad.
I know what you mean about doctors. My husband's doctor won't raise his thyroid meds even though we know his hypothyroidism is directly impacting his cholesterol ratio.
 

Similar threads

Back
Top Bottom